Japan, Oct. 23 -- NEC Bio will be presenting results from the Phase I/II TNBC clinical trial of its orally administered individualized neoantigen therapy, NECVAX-NEO1, used in combination with checkpoint inhibitors (CPIs) and chemotherapy for patients with triple-negative breast cancer (TNBC). The findings are being presented in an e-poster at the ESMO Congress in Madrid, Spain, from October 23 to 27, 2026.NECVAX-NEO1 is an AI powered individualized bacteria-based oral DNA therapy that combines IMMUNASIGHT(R), NEC Bio's proprietary AI based neoantigen prediction platform for identifying the most immunogenic patient-specific neoepitopes, with TORAPRIME(R), its proprietary oral bacterial neoantigen delivery platform. This therapy is designed ...